$QLGN keywords "ready the technology for market" LOUISVILLE, Ky. (WAVE) – A technology believed to block COVID-19 from infecting human cells that was developed at the University of Louisville now has a commercial partner. Qualigen Therapeutics Inc., based in California, signed a license agreement and plans to fund continued development with UofL to ready the technology for market, according to the university. According to UofL, the research involves an aptamer, which is a piece of synthetic DNA and was originally developed as a cancer treatment.
  • 3